Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALYPSO: Caelyx-Carboplatin vs Paclitaxel-Carboplatin in Relapsed Ovarian Cancer
NCT00189553Phase 3Completed
- Sponsor
- ARCAGY
- Start
- Apr 2005
- Primary completion
- Jan 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by ARCAGY. Primary endpoint: Progression-Free Survival at 5 years. Started Apr 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00189553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189553.